OREANDA-NEWS. Ablynx today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Adrianus van Herk and Van Herk Investments B.V.

Van Herk Investments B.V. notified Ablynx that they have crossed the 5% threshold on 9 August 2016 as a result of the acquisition of Ablynx shares, including 1,835,276 Ablynx shares previously held by Adrianus van Herk. As a result of the transactions, Adrianus van Herk no longer holds Ablynx shares with Van Herk Investments B.V. now holding 3,290,357 Ablynx shares. The latter representing a 5.40% of the current 60,910,744 outstanding Ablynx shares.

Van Herk Investments B.V. is controlled by Adrianus van Herk in accordance with Articles 5 and 7 of the Dutch Companies Code.

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium.